Houston TX 多发性骨髓瘤临床试验
39项针对 多发性骨髓瘤的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
招募中3 期
- Houston Methodist Cancer Center Infusion, Houston
- Houston Methodist Hospital - Department of Pharmacy, Houston
- Houston Methodist Hospital Cancer Center, Houston
- 以及另外 3 项
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
招募中3 期
- MD Anderson Cancer Center, Houston
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- Oncology Consultants /ID# 268323, Houston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
招募中4 期
- MD Anderson Cancer Center, Houston
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
招募中3 期
- Houston Methodist Hospital, Houston
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
招募中1 期
- MD Anderson Cancer Center, Houston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- MD Anderson Cancer Center, Houston
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
招募中观察性研究
- MDA, Houston
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
招募中2 期欢迎健康志愿者
- MD Anderson Cancer Center, Houston
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
招募中1 期
- Houston Methodist Hospital, Houston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
招募中3 期
- University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
招募中3 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
招募中1 期
- Oncology Consultants, Houston
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
招募中3 期
- Research Site, Houston
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
招募中2 期
- M D Anderson Cancer Center, Houston
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
招募中1/2 期
- Research Site, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
招募中3 期
- The University of Texas MD Anderson Cancer Center, Houston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Houston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中2 期
- University of Texas MD Anderson Cancer Center, Houston
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
招募中3 期
- Research Site, Houston
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
招募中1 期
- Research Site, Houston
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
招募中1/2 期
- MD Anderson, Houston
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
招募中1 期
- Oncology Consultants (P1 Trials -Exigent Network), Houston
- Lumi Research, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
招募中2 期
- MD Anderson Cancer Center, Houston
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
招募中1/2 期
- University of Texas MD Anderson Cancer Center, Houston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
招募中1/2 期
- MD Anderson Cancer Center, Houston
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
招募中3 期
- Research Site, Houston
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
招募中1/2 期
- M D Anderson Cancer Center, Houston
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
招募中2 期
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
招募中1/2 期
- M D Anderson Cancer Center, Houston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
招募中3 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- M D Anderson Cancer Center, Houston
- 以及另外 2 项
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
招募中观察性研究
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- MD Anderson Cancer Center, Houston
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
招募中1/2 期
- Houston Methodist Neal Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- MDACC, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
招募中1/2 期
- University of Texas MD Anderson Cancer Center, Houston
其他城市的 多发性骨髓瘤试验
- New York City, NY59 项研究
- Boston, MA45 项研究
- Atlanta, GA42 项研究
- Durham, NC36 项研究
- Nashville, TN31 项研究
- Denver, CO26 项研究
- St. Louis, MO26 项研究
- Rochester, MN25 项研究
- Columbus, OH25 项研究
- Chicago, IL24 项研究
- Milwaukee, WI23 项研究
- Baldwin Park, CA23 项研究
Houston的其他研究
- 非小细胞肺癌143 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）124 项研究
- 结直肠癌101 项研究
- 转移性癌症100 项研究
- 卵巢癌90 项研究
- 急性髓系白血病88 项研究
- 肺癌78 项研究
- 前列腺癌73 项研究
- 子宫内膜癌69 项研究
- 黑色素瘤61 项研究
- 胰腺癌59 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。